EpiPharm AG is a clinical-stage biopharmaceutical company focused on development to market of innovative, non-invasive, take home topical products for the treatment of benign skin tumours and hyperpigmentation disorders. EPI-SK17, EpiPharm’s lead product is the first therapy that treats the cause of seborrheic keratosis, the underlying tumour formation and growth.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.